- PAVmed established an interesting hub and spoke business model with joint services and selling stakes in commercially ready technologies.
- This opens up new financing streams and potentially a lot of value creation for PAVmed shareholders.
- But near-term, the viability depends on things going right for Lucid, which is not guaranteed.
- Still, given the potential, we think PAVM is cheap enough for a speculative position.
- Looking for more investing ideas like this one? Get them exclusively at SHU Growth Portfolio. Learn More »
PAVmed: Lots Of Potential But EsoGuard Determines Short-Term Progress